Alemtuzumab (Campath-1H) is a powerful lymphocyte depleting antibody (anti-CD52) that has been used as induction immunosuppresion in cardiac transplant patients. Genetic expression profiling (GEP) of mononuclear cells has been proposed as a non-invasive monitoring test to rule out cardiac rejection, thus decreasing the number of routine surveillance endomyocardial biopsies performed. There is no data regarding the effect on GEP scores exerted by immunosuppression induction with Alemtuzumab. Our objective was to analyze the effect of Alemtuzumab on the GEP scores in cardiac recipients.
Loyaga-Rendon Renzo Y合作论文数2Chaparro Sandra V合作论文数Department of Medicine, University of Miami Miller School of Medicine2
Si M Pham合作论文数North Shore University Hospital2Henry Quevedo合作论文数1Hz Zhu合作论文数1sarah eckenrode s合作论文数1Jx She合作论文数1Kara Hamilton合作论文数1C Collins合作论文数1
Chuang Liu合作论文数1
Gary W Beecham合作论文数Department of Human Genetics, Miller School of Medicine, University of Miami;John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami1Pascal J. Goldschmidt-Clermont合作论文数1
David R. Nelson合作论文数Department of Physics, Harvard University1
Regino gonzalez-peralta合作论文数1
Margaret Pericak-Vance合作论文数John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami1Leonardo Tamariz合作论文数1Namrata Sikka合作论文数1David Seo合作论文数1
